n November 30, 2022, Neoleukin Therapeutics, Inc. (the “Company”) filed the Amended and Restated Bylaws as approved and adopted by the Company’s board of directors (the “Board”). On January 7, 2023, the Company filed updated Amended and Restated Bylaws to correct incorrect references and page numbers within the table of contents, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.
Download